According to Reuters reports (London), researchers said that even though swift progress in cancer research has boosted the development of many new oncology drugs, but due to a setback in approvals and regulations, patients in Europe have to wait for years until the drug is legally approved by the organization.
As per the report directed by Britain’s ICR (Institute for Cancer Research), the average time required launching the drug in the market by obtaining the marketing license being granted by EMA (European Medicines Agency) regulators from the beginning of the drug’s early development stage or Phase 1 was 9.1 Years during 2009-2016. While during 2000-2008, the estimated approval time was 7.8 Years.
Along with this, the reports found the major variation in the developmental rates of new specific cancer-related drugs, which include 15 approved drugs in Europe for breast cancer, but not a single drug for a brain tumor within the time span from the year 2000 to 2016.
Paul Workman, chief executive of ICR, who also directed this research—said that the findings revealed the stunning situation of the state related to cancer drug innovation, development, approval, and appraisal.
Even though unbelievable scientific and technological advancements have been noticed over the past decade that is stimulating the extensive research over drug development, but still, more efforts are required to develop more innovative treatments that would be accessible to patients.
According to ICR researchers, as per continuous progression in studying cancer genetics and recognizing the disease, there should be relatively quicker development in cancer drug sector as clinical trials for targeted treatment can be accepted on less number of smartly selected patients on the basis of genetically linked cancer.
At present, there are very few medicines approved for children and patients with cancers developed up to critical stages. Between the years 2000 to 2016, there were zero drugs approved for the treatment of oesophageal, brain, bladder or womb cancer, and only a single drug was approved for liver cancer.